vs
NEOGEN CORP（NEOG）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是BRC Group Holdings, Inc.的1.2倍（$224.7M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs -7.1%，领先55.0%），NEOGEN CORP同比增速更快（-2.8% vs -21.9%），过去两年NEOGEN CORP的营收复合增速更高（-0.9% vs -15.4%）
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
NEOG vs RILY — 直观对比
营收规模更大
NEOG
是对方的1.2倍
$188.3M
营收增速更快
NEOG
高出19.0%
-21.9%
净利率更高
RILY
高出55.0%
-7.1%
两年增速更快
NEOG
近两年复合增速
-15.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $224.7M | $188.3M |
| 净利润 | $-15.9M | $90.3M |
| 毛利率 | 47.5% | 79.5% |
| 营业利润率 | -2.4% | 32.3% |
| 净利率 | -7.1% | 47.9% |
| 营收同比 | -2.8% | -21.9% |
| 净利润同比 | 96.5% | 1710.8% |
| 每股收益（稀释后） | $-0.07 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOGRILY
| Q4 25 | $224.7M | $188.3M | ||
| Q3 25 | $209.2M | $215.3M | ||
| Q2 25 | $225.4M | $188.2M | ||
| Q1 25 | $221.0M | $197.2M | ||
| Q4 24 | $231.3M | $241.0M | ||
| Q3 24 | $217.0M | $225.5M | ||
| Q2 24 | $236.8M | $256.0M | ||
| Q1 24 | $228.8M | $263.4M |
净利润NEOGRILY
| Q4 25 | $-15.9M | $90.3M | ||
| Q3 25 | $36.3M | $91.1M | ||
| Q2 25 | $-612.3M | $139.5M | ||
| Q1 25 | $-10.9M | $-10.0M | ||
| Q4 24 | $-456.3M | $-5.6M | ||
| Q3 24 | $-12.6M | $-284.4M | ||
| Q2 24 | $-5.4M | $-433.6M | ||
| Q1 24 | $-2.0M | $-49.2M |
毛利率NEOGRILY
| Q4 25 | 47.5% | 79.5% | ||
| Q3 25 | 45.4% | 83.7% | ||
| Q2 25 | 41.2% | 81.3% | ||
| Q1 25 | 49.9% | 81.4% | ||
| Q4 24 | 49.0% | 79.8% | ||
| Q3 24 | 48.4% | 82.1% | ||
| Q2 24 | 47.9% | 84.5% | ||
| Q1 24 | 51.1% | 85.3% |
营业利润率NEOGRILY
| Q4 25 | -2.4% | 32.3% | ||
| Q3 25 | -7.7% | 30.4% | ||
| Q2 25 | -271.1% | 5.7% | ||
| Q1 25 | 2.4% | -31.2% | ||
| Q4 24 | -197.8% | -69.2% | ||
| Q3 24 | 1.0% | -36.4% | ||
| Q2 24 | 5.5% | -90.8% | ||
| Q1 24 | 5.3% | -6.1% |
净利率NEOGRILY
| Q4 25 | -7.1% | 47.9% | ||
| Q3 25 | 17.4% | 42.3% | ||
| Q2 25 | -271.6% | 74.1% | ||
| Q1 25 | -4.9% | -5.1% | ||
| Q4 24 | -197.3% | -2.3% | ||
| Q3 24 | -5.8% | -126.1% | ||
| Q2 24 | -2.3% | -169.4% | ||
| Q1 24 | -0.9% | -18.7% |
每股收益（稀释后）NEOGRILY
| Q4 25 | $-0.07 | $2.78 | ||
| Q3 25 | $0.17 | $2.91 | ||
| Q2 25 | $-2.82 | $4.50 | ||
| Q1 25 | $-0.05 | $-0.39 | ||
| Q4 24 | $-2.10 | $-0.01 | ||
| Q3 24 | $-0.06 | $-9.39 | ||
| Q2 24 | $-0.02 | $-14.35 | ||
| Q1 24 | $-0.01 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.3M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $2.1B | $-171.5M |
| 总资产 | $3.4B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NEOGRILY
| Q4 25 | $145.3M | $226.6M | ||
| Q3 25 | $138.9M | $184.2M | ||
| Q2 25 | $129.0M | $267.4M | ||
| Q1 25 | $127.7M | $138.3M | ||
| Q4 24 | $140.2M | $146.9M | ||
| Q3 24 | $120.5M | $159.2M | ||
| Q2 24 | $170.9M | $236.9M | ||
| Q1 24 | $168.4M | $190.7M |
总债务NEOGRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益NEOGRILY
| Q4 25 | $2.1B | $-171.5M | ||
| Q3 25 | $2.1B | $-260.5M | ||
| Q2 25 | $2.1B | $-351.7M | ||
| Q1 25 | $2.7B | $-496.8M | ||
| Q4 24 | $2.7B | $-488.2M | ||
| Q3 24 | $3.1B | $-497.6M | ||
| Q2 24 | $3.1B | $-218.3M | ||
| Q1 24 | $3.1B | $228.4M |
总资产NEOGRILY
| Q4 25 | $3.4B | $1.7B | ||
| Q3 25 | $3.4B | $1.7B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $4.0B | $1.5B | ||
| Q4 24 | $4.1B | $1.8B | ||
| Q3 24 | $4.5B | $2.2B | ||
| Q2 24 | $4.5B | $3.2B | ||
| Q1 24 | $4.6B | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $7.8M | — |
| 自由现金流率自由现金流/营收 | 3.5% | — |
| 资本支出强度资本支出/营收 | 5.2% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $-18.5M | — |
8季度趋势，按日历期对齐
经营现金流NEOGRILY
| Q4 25 | $19.4M | $26.2M | ||
| Q3 25 | $10.9M | $-60.6M | ||
| Q2 25 | $16.4M | $-25.6M | ||
| Q1 25 | $19.5M | $184.0K | ||
| Q4 24 | $40.3M | $-2.7M | ||
| Q3 24 | $-17.9M | $19.5M | ||
| Q2 24 | $26.7M | $111.5M | ||
| Q1 24 | $-30.2M | $135.4M |
自由现金流NEOGRILY
| Q4 25 | $7.8M | — | ||
| Q3 25 | $-13.1M | — | ||
| Q2 25 | $349.0K | — | ||
| Q1 25 | $-13.4M | — | ||
| Q4 24 | $23.1M | — | ||
| Q3 24 | $-56.3M | — | ||
| Q2 24 | $2.5M | — | ||
| Q1 24 | $-62.3M | — |
自由现金流率NEOGRILY
| Q4 25 | 3.5% | — | ||
| Q3 25 | -6.3% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | -6.1% | — | ||
| Q4 24 | 10.0% | — | ||
| Q3 24 | -26.0% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | -27.2% | — |
资本支出强度NEOGRILY
| Q4 25 | 5.2% | — | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | 7.1% | — | ||
| Q1 25 | 14.9% | — | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 17.7% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | 14.0% | — |
现金转化率NEOGRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | 0.30× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
